. Quote from Pierre-Alain Ruffieux, Chief Executive Officer, Lonza: “We congratulate Moderna on this important milestone, which represents a significant scientific achievement and serves as a testament to Moderna’s […]
Autor: Firma Lonza Group Ltd.
Lonza Welcomes New Group Chief Executive Officer Pierre-Alain Ruffieux
Pierre-Alain Ruffieux today commences his role as Chief Executive Officer, following his appointment in June 2020. Albert M. Baehny resumes his role as Chairman of the Board of Directors, after […]
Investor Update Details Business Structure, Divisional Dynamics, New External Reporting and Guidance
Lonza provides the details of its new structural design, culture and external reporting 2023 Group guidance: double-digit sales growth, CORE EBITDA margin of around 33% – 35% and double-digit ROIC […]
Lonza’s Pharma Biotech Business Drives Strong H1 2020 Group Sales Growth and Margin Improvement
Strong operational performance maintained during COVID-19; sites remained open and protection of employees continues to be a top priority Landmark ten-year collaboration with Moderna on the mRNA1 platform. The current focus […]
Sven Abend Leaves Lonza to Take CEO Position in Germany
• Sven Abend has decided to resign from Lonza to take a CEO position in Germany. • Recruitment plans are under way to appoint a permanent replacement. • LSI is […]
Lonza Appoints New Chief Executive Officer
The Board of Lonza announced today that Pierre-Alain Ruffieux has been appointed Chief Executive Officer effective 1 November 2020. Pierre-Alain is currently Head of Global Pharma Technical Operations at […]
Moncef Slaoui to Step Down as Member of the Board of Directors of Lonza Group
Dr Moncef Slaoui has decided to step down from his position as a member of the Lonza Group Board of Directors, following his appointment to the role of Chief Advisor […]